Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marija Balic

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Iscience|October 27, 2025
Evaluation of urinary cfDNA workflows for the molecular profiling of malignant diseaseAnna Eberhard, Tina Moser, Leandra Ziegler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8Martin Filipits, Margaretha Rudas, Verena Kainz, et al.
Cancer Medicine|March 17, 2022
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer studyDominik A Barth, Stefanie Stanzer, Jasmin Spiegelberg, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
Quantitative and qualitative patient-reported analysis of misdiagnosis and/or late diagnosis of metastatic lobular cancerMorgan Elizabeth Cody, Hung-Ching Rick Chang, Julia Foldi, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F Singer, Yen Y Tan, Florian Fitzal, et al.
Cancers|August 23, 2020
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center StudyJakob M Riedl, Dominik A Barth, Wolfgang M Brueckl, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR StudyNadia Harbeck, Denise Wrobel, Matthias Zaiss, et al.
NPJ Breast Cancer|April 8, 2026
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 TrialDaniel Egle, Dominik Hlauschek, Simon Peter Gampenrieder, et al.
Future Oncology (London, England)|June 22, 2026
Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-BreastJulia Foldi, Gregory Hogan, Katherine Johansen Taber, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Iscience|October 27, 2025
Evaluation of urinary cfDNA workflows for the molecular profiling of malignant diseaseAnna Eberhard, Tina Moser, Leandra Ziegler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8Martin Filipits, Margaretha Rudas, Verena Kainz, et al.
Cancer Medicine|March 17, 2022
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer studyDominik A Barth, Stefanie Stanzer, Jasmin Spiegelberg, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
Quantitative and qualitative patient-reported analysis of misdiagnosis and/or late diagnosis of metastatic lobular cancerMorgan Elizabeth Cody, Hung-Ching Rick Chang, Julia Foldi, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F Singer, Yen Y Tan, Florian Fitzal, et al.
Cancers|August 23, 2020
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center StudyJakob M Riedl, Dominik A Barth, Wolfgang M Brueckl, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR StudyNadia Harbeck, Denise Wrobel, Matthias Zaiss, et al.
NPJ Breast Cancer|April 8, 2026
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 TrialDaniel Egle, Dominik Hlauschek, Simon Peter Gampenrieder, et al.
Future Oncology (London, England)|June 22, 2026
Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-BreastJulia Foldi, Gregory Hogan, Katherine Johansen Taber, et al.
Pageof 13